KRAS Inhibitor Shrinks Tumors in Over 40% of NSCLC Patients

(MedPage Today) -- CHICAGO -- More than 40% of patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) responded to treatment with adagrasib, findings from a phase II trial showed. Among 112 evaluable patients in the KRYSTAL-1 study...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news